Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) FCF Margin (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed FCF Margin for 14 consecutive years, with 48.02% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 1535.0% year-over-year to 48.02%, compared with a TTM value of 27.29% through Dec 2025, up 363.0%, and an annual FY2025 reading of 27.29%, up 363.0% over the prior year.
  • FCF Margin was 48.02% for Q4 2025 at Neurocrine Biosciences, up from 28.78% in the prior quarter.
  • Across five years, FCF Margin topped out at 48.02% in Q4 2025 and bottomed at 29.92% in Q1 2023.
  • Average FCF Margin over 4 years is 23.78%, with a median of 25.8% recorded in 2024.
  • Peak annual rise in FCF Margin hit 5304bps in 2024, while the deepest fall reached -2734bps in 2024.
  • Year by year, FCF Margin stood at 36.86% in 2021, then crashed by -36bps to 23.66% in 2023, then skyrocketed by 38bps to 32.67% in 2024, then soared by 47bps to 48.02% in 2025.
  • Business Quant data shows FCF Margin for NBIX at 48.02% in Q4 2025, 28.78% in Q3 2025, and 14.95% in Q2 2025.